About neuren pharmaceuticals ltd - NURPF
Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. It operates through the Commercial Products, and Research and Development segments. The Commercial Products segment refers to the milestone and royalty revenue from license of intellectual property. The Research and Development segment focuses on the development of pharmaceutical products for the treatment of neurodevelopmental disorders. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.
NURPF At a Glance
Neuren Pharmaceuticals Ltd.
117 Camberwell Road
Melbourne, Victoria (VIC) 3123
| Phone | 61-3-9092-0480 | Revenue | 41.68M | |
| Industry | Pharmaceuticals: Generic | Net Income | 19.63M | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NURPF Valuation
| P/E Current | 53.725 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 81.112 |
| Price to Sales Ratio | 38.939 |
| Price to Book Ratio | 6.963 |
| Price to Cash Flow Ratio | 20.07 |
| Enterprise Value to EBITDA | 100.266 |
| Enterprise Value to Sales | 34.201 |
| Total Debt to Enterprise Value | N/A |
NURPF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 2.355 |
| Total Asset Turnover | 0.173 |
NURPF Liquidity
| Current Ratio | 76.604 |
| Quick Ratio | 76.604 |
| Cash Ratio | 68.278 |
NURPF Profitability
| Gross Margin | 99.964 |
| Operating Margin | 34.075 |
| Pretax Margin | 60.23 |
| Net Margin | 47.09 |
| Return on Assets | 8.138 |
| Return on Equity | 8.703 |
| Return on Total Capital | 8.695 |
| Return on Invested Capital | 8.703 |
NURPF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |